Protease inhibitor plasma concentrations associate with COVID-19 infection. (2021)
Attributed to:
Phase 1 COVID-19 Immunity - National Core Study
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/oxfimm/iqab014
PubMed Identifier: 34458849
Publication URI: http://europepmc.org/abstract/MED/34458849
Type: Journal Article/Review
Volume: 2
Parent Publication: Oxford open immunology
Issue: 1
ISSN: 2633-6960